¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦35Â÷ ´ëÇÑ´ç´¢º´ÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2022-05-13

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Á¦35Â÷ ´ëÇÑ´ç´¢º´ÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2022-05-13
±³À°ÀÏÀÚ : 2022-05-13
±³À°Àå¼Ò : °æÁÖ È­¹éÄÁº¥¼Ç¼¾ÅÍ  
±³À°ÁÖÁ¦ : Á¦35Â÷ ´ëÇÑ´ç´¢º´ÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ
´ã´çÀÚ : ÀÌ¿¬ÁÖ
¿¬¶ôó : 02-714-9071  
À̸ÞÀÏ : diabetes@kams.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 1300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 6 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 170,000¿ø      
ºñ°í È¸¿ø ÀÇ»ç: 120,000¿ø ºñȸ¿ø ÀÇ»ç: 170,000¿ø ȸ¿ø ºñÀÇ»ç: 70,000¿ø ºñȸ¿ø ºñÀÇ»ç: 120,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 08:30~08:50 Initial combination therapy for T2DM; for whom, what is the optimal combination?  ¹ÚÁ¤È¯(ÇѾçÀÇ´ë ³»°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 09:00~09:25 Effect of SGLT2 inhibitors in heart failure with preserved ejection fraction  ½ÉÁö¿µ(¿¬¼¼ÀÇ´ë ½ÉÀå³»°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 09:25~09:50 Cardiovascular and renal outcomes with Finerenone with type 2 diabetes with CKD  È²Çö¼®(°æÈñÀÇ´ë ½ÅÀå³»°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 09:50~10:15 Post-hoc analysis of AMPLITUDE-O study (CVOT study of Efpeglenatide)  ¹é½ÂÀç(Çѹ̾àÇ° ½Å¾àÀӻ󰳹ߺ»ºÎ) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 10:15~10:40 Safety and efficacy of GLP-1/GIP dual agonists in patients with type 2 diabetes  Á¶¿µ¹Î(¼­¿ïÀÇ´ë ³»°ú) 
Åä·Ð 05-13 °æÁÖ HICO Room1 10:40~11:00 Panel discussion  Á¤Ã¢ÈñÀ̻󿭼­¹ÌÇýÀ±ÁöÈñ(¿ï»êÀÇ´ë ³»°ú°æÈñÀÇ´ë ³»°ú¼øõÇâÀÇ´ë ³»°úÀü³²ÀÇ´ë ³»°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 11:30~12:10 Tirzepatide: a dual GIP and GLP-1 receptor agonist in development for the treatment of type 2 diabetes, obesity and non-alcoholic steatohepatitis  Juan Pablo Frias(Velocity Clinical Research USA) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 12:10~13:20 Intermittently scanned CGM: clinical evidence and practical tips  Áø»ó¸¸(¼º±Õ°üÀÇ´ë ³»°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 14:50~15:30 Sirtuin 6 as a multitasking player in immune cell differentiation and metabolic diseases  ¹Úº´Çö(ÀüºÏÀÇ´ë »ýÈ­ÇкÐÀÚ»ý¹°Çб³½Ç) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room2 15:50~16:20 Self-care solutions for GDM patients  ¹ÚÇýÀº(°æÈñÀÇ·á¿ø °£È£°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room2 16:20~16:50 Self-care solutions for children and adolescents with diabetes  À̽ÂÈñ(°æºÏ´ëÇб³¾î¸°À̺´¿ø °£È£°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room2 16:50~17:20 Self-care solutions for young diabetic patients  ±è¼±¿µ(»ï¼º¼­¿ïº´¿ø °£È£°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room2 17:20~17:50 Self-care solutions for elderly diabetic patients  ¹Ú¼±¿µ(°è¸í´ëÇб³ µ¿»êÀÇ·á¿ø °£È£°ú) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦35Â÷ ´ëÇÑ´ç´¢º´ÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2022-05-13""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022³âµµ ÀÇ°ú´ëÇÐ ±³À°°úÁ¤ °³¹ß°ú Æò°¡ ¿öÅ©¼ó(2ÀÏÂ÷) : 2022-05-14
´ÙÀ½±Û 2022³âµµ ÀÇ°ú´ëÇÐ ±³À°°úÁ¤ °³¹ß°ú Æò°¡ ¿öÅ©¼ó(1ÀÏÂ÷) : 2022-05-13
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20775 ¼­¿ï 2024³â °áÇÙ°ü¸®±³À° 1±â(1ÀÏÂ÷) : 2024-06-13 0 2 2024-05-27
20774 ºÎ»ê (¿Â¶óÀÎ) ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ ºÎ»ê¡¤¿ï»ê¡¤°æ³² ÁöºÎȸ 2024³â 06¿ù Çмú´ëȸ : 2024-06-13 0 4 2024-05-27
20773 ´ëÀü 2024 Á¦40ȸ ´ëÇѼҾƿܰúÇÐȸ Ãá°èÇмú´ëȸ ¹× 40Áֳ⠱â³äÇà»ç(1ÀÏÂ÷) : 2024-06-13 0 2 2024-05-27
20772 ´ë±¸ 2024 Á¦2Â÷ ´ëÇѺñ´¢ÀÇÇÐȸ ´ë±¸°æºÏÁöºÎÇÐȸ : 2024-06-13 0 6 2024-05-27
20771 ¼­¿ï ´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ 2024³â Á¦19Â÷ Çмú´ëȸ (1ÀÏÂ÷) : 2024-06-13 0 10 2024-05-27
20770 ¼­¿ï 2024 ´ëÇÑÈ­»óÇÐȸ Çмú´ëȸ(1ÀÏÂ÷) : 2024-06-13 0 3 2024-05-27
20769 ¼­¿ï 2024³â ±Ýõ±¸ÀÇ»çȸ 1Â÷ ¿¬¼ö±³À°(¿ì¿ïÁõ ¾àÁ¦, ÇǺÎÁúȯ, CBC¿Í LFT, À§¿°) : 2024-06-12 0 1 2024-05-27
20768 ¼­¿ï 2024 Á¦3ȸ ÀÌ°ÇÈñ ¼Ò¾Æ¾Ï¡¤Èñ±ÍÁúȯ ±Øº¹»ç¾÷ ¿¬±¸ÀÚ SKILL-UP Workshop : 2024-06-12 0 1 2024-05-27
20767 °æ±â ´ëÇÑÇǺΰúÇÐȸ Á¦78Â÷ °æ±âÁöºÎȸ ÇмúÁý´ãȸ : 2024-06-11 0 1 2024-05-27
20766 ±¤ÁÖ Á¦180Â÷ ´ëÇѼҾÆû¼Ò³â°úÇÐȸ ±¤ÁÖ¡¤Àü³²Áöȸ ÇмúÁý´ãȸ : 2024-06-11 0 6 2024-05-27
20765 ºÎ»ê ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ºÎ»ê,¿ï»ê,°æ³²Áöȸ - Á¦362Â÷ ¿ù·ÊÇмúȸ : 2024-06-11 0 10 2024-05-27
20764 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ±âº»±³À° : 2024-06-11 0 5 2024-05-27
20763 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ(ÀÇ»ç) ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ½ÉÈ­±³À° : 2024-06-11 0 7 2024-05-27
20762 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼҾÆÀÀ±ÞÀÇÇÐȸ Á¦ 32ȸ Á¤±â Áý´ãȸ : 2024-06-10 0 9 2024-05-27
20761 ¼­¿ï °í·Á´ëÇб³±¸·Îº´¿ø Á¦16ȸ KOALA Symposium 2024 : 2024-06-09 0 1 2024-05-27
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷